Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer.

Kiyoshi Yoshino,Shoji Kamiura,Haruki Ogawa,Atsushi Tokuhira,Masahiko Takemura,Kenjiro Sawada,Yutaka Ueda,Seiji Mabuchi,Masami Fujita,Tateki Tsutsui,Tadashi Kimura

Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer.

2017

Kiyoshi Yoshino
Shoji Kamiura
Haruki Ogawa
Atsushi Tokuhira
Masahiko Takemura
Kenjiro Sawada
Yutaka Ueda
Seiji Mabuchi
Masami Fujita
Tateki Tsutsui
Tadashi Kimura

5538 Background: Development of new regimen is required to overcome platinum resistant ovarian cancer. Irinotecan and gemcitabine have a synergistic effect to inhibit the growth of ovarian cancer c...

Keywords:

Pathology
Irinotecan
Taxane
Gemcitabine
Ovarian cancer
Oncology
Fallopian tube
Chemotherapy
Regimen
Peritoneal cancer
Internal medicine
Medicine
Cancer research
platinum resistant
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations